Commercial production market environment

Historically DDTS were developed in environments where the primary goal was proof of concept , rather than developing a commercial product. The typical pharmaceutical considerations described above were not dealt with seriously in the early days of drag carrier research, thus early drug-carrier systems were associated with long gestation periods from product development to product marketing. 

Finally, a crucial aspect to drive the implementation of these products in the market is the acceptance of the public regarding the safety of the end-user product. Nowadays, there is a lack of information about the possible negative effects of nano-additives in the environment and human health. Nano-safety research is focused on the fate of nanomaterials once incorporated in commercial products, and great effort is being done to assess the toxicology of the nanomaterials, so appropriate guidelines to handle, store and use of nanomaterials should be developed. 

The company has changed its strategy and its underlying assumptions fundamentally in the course of the project. For example, it has learned that it needs to price the product based on long-term positioning rather than current cost, that it needs to build a plant in a low-cost environment, that value chain intermediaries will need an incentive to adopt its product, and that it is sometimes necessary to work with smaller attackers as initial commercialization partners to demonstrate proof of principle, create market pull, and get the big fish to adopt a new product. The increased focus, clear product positioning, and partnering has already resulted in a number of major market introductions over the past year. 

---